MiMedx's AmnioFix Injectable meets in Phase IIb for plantar fasciitis

MiMedx Group Inc. (NASDAQ:MDXG) reported top-line data from the single-blind, U.S. Phase IIb IND trial in 145 patients with plantar fasciitis showing that a single 40 mg dose of AmnioFix Injectable met the primary endpoint of improving visual analog scale (VAS) score for pain from baseline to three months vs. placebo (54.1 vs. 31.9 points, p<0.0001). AmnioFix Injectable also met the secondary endpoint of improving Foot Function Index-Revised (FFI-R) score from baseline to three months vs. placebo (36 vs. 22 points, p=0.0004)...